(Q36521029)

14 August 2017

1 reference

title

Selective PPAR agonists for the treatment of type 2 diabetes (English)

1 reference

14 August 2017

1 reference

Jan O Nehlin

1

1 reference

14 August 2017

John P Mogensen

2

1 reference

14 August 2017

Ingrid Petterson

3

1 reference

14 August 2017

Lone Jeppesen

4

1 reference

14 August 2017

Jan Fleckner

5

1 reference

14 August 2017

Erik M Wulff

6

1 reference

14 August 2017

Per Sauerberg

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Annals of the New York Academy of Sciences

14 August 2017

published in

1 reference

14 August 2017

volume

1067

1 reference

14 August 2017

page(s)

448-453

1 reference

Type 2 diabetes: principles of pathogenesis and therapy

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

PPAR ligands for metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

PPARs and the complex journey to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

PPARs: therapeutic targets for metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

Peroxisome proliferator-activated receptor γ in diabetes and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

Transforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

Structure-activity relationships of dimeric PPAR agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1354.064

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1354.064

1 reference

14 August 2017

1 reference